Radwa El Borolossy1, Lamia Mohamed El Wakeel2, Ihab El Hakim3, Nagwa Sabri1. 1. Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, 4 Street 292, New Maadi, Cairo, Egypt. 2. Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, 4 Street 292, New Maadi, Cairo, Egypt. lamywak@yahoo.com. 3. Department of Pediatrics, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Abstract
BACKGROUND:Hyperphosphatemia is a common problem in patients with end-stage renal disease (ESRD) who are on maintenance hemodialysis (HD) and contributes to the development of secondary hyperparathyroidism and cardiovascular complications. Nicotinamide (NAM) has been shown in some studies to inhibit intestinal and renal sodium/phosphorus co-transporters and reduce serum phosphorus levels. We have therefore evaluated the efficacy and safety of NAM as adjunctive therapy to calcium-based phosphate binders to control hyperphosphatemia in hemodialysis patients. METHODS:Sixty pediatric HD outpatients were randomly divided into two equally sized groups (30 children each). One group received calcium-based phosphate binder (control group), and the other received both the calcium-based phosphate binder + NAM at a dose of 100 mg twice or three times daily (nicotinamide group). Both groups were followed for a 6-month period. RESULTS: Over the 6-month treatment period, children in the NAM group showed a significant decline in the levels of serum phosphorus (p = 0.0001), serum calcium-phosphorus (Ca × P; p = 0.0001) product and parathyroid hormone (p = 0.02) versus baseline values and those of the control group. After 6 months of NAM treatment, the mean serum high-density lipoprotein cholesterol levels had increased significantly (p = 0.01), and the median serum triglyceride levels had decreased (p = 0.009). There was no significant change in any of these parameters among the children of the control group. The major adverse events associated with the NAM therapy were diarrhea, flushing and nausea. CONCLUSION: The addition of NAM to therapy with phosphate binders is effective in lowering phosphorus levels and has a beneficial effect on the lipid profile with only mild side effects.
RCT Entities:
BACKGROUND:Hyperphosphatemia is a common problem in patients with end-stage renal disease (ESRD) who are on maintenance hemodialysis (HD) and contributes to the development of secondary hyperparathyroidism and cardiovascular complications. Nicotinamide (NAM) has been shown in some studies to inhibit intestinal and renal sodium/phosphorus co-transporters and reduce serum phosphorus levels. We have therefore evaluated the efficacy and safety of NAM as adjunctive therapy to calcium-based phosphate binders to control hyperphosphatemia in hemodialysis patients. METHODS: Sixty pediatric HD outpatients were randomly divided into two equally sized groups (30 children each). One group received calcium-based phosphate binder (control group), and the other received both the calcium-based phosphate binder + NAM at a dose of 100 mg twice or three times daily (nicotinamide group). Both groups were followed for a 6-month period. RESULTS: Over the 6-month treatment period, children in the NAM group showed a significant decline in the levels of serum phosphorus (p = 0.0001), serum calcium-phosphorus (Ca × P; p = 0.0001) product and parathyroid hormone (p = 0.02) versus baseline values and those of the control group. After 6 months of NAM treatment, the mean serum high-density lipoprotein cholesterol levels had increased significantly (p = 0.01), and the median serum triglyceride levels had decreased (p = 0.009). There was no significant change in any of these parameters among the children of the control group. The major adverse events associated with the NAM therapy were diarrhea, flushing and nausea. CONCLUSION: The addition of NAM to therapy with phosphate binders is effective in lowering phosphorus levels and has a beneficial effect on the lipid profile with only mild side effects.
Authors: Braden Manns; Lesley Stevens; Dana Miskulin; William F Owen; Wolfgang C Winkelmayer; Marcello Tonelli Journal: Kidney Int Date: 2004-09 Impact factor: 10.612
Authors: Isabelle Six; Julien Maizel; Fellype C Barreto; Ashraf Y Rangrez; Sébastien Dupont; Michel Slama; Christophe Tribouilloy; Gabriel Choukroun; Jean Claude Mazière; Stefanie Bode-Boeger; Jan T Kielstein; Tilman B Drüeke; Ziad A Massy Journal: Cardiovasc Res Date: 2012-07-20 Impact factor: 10.787
Authors: Santhi K Ganesh; Austin G Stack; Nathan W Levin; Tempie Hulbert-Shearon; Friedrich K Port Journal: J Am Soc Nephrol Date: 2001-10 Impact factor: 10.121
Authors: Joachim H Ix; Tamara Isakova; Brett Larive; Kalani L Raphael; Dominic S Raj; Alfred K Cheung; Stuart M Sprague; Linda F Fried; Jennifer J Gassman; John P Middleton; Michael F Flessner; Geoffrey A Block; Myles Wolf Journal: J Am Soc Nephrol Date: 2019-05-13 Impact factor: 10.121
Authors: Lucy A Oakey; Rachel S Fletcher; Yasir S Elhassan; David M Cartwright; Craig L Doig; Antje Garten; Alpesh Thakker; Oliver D K Maddocks; Tong Zhang; Daniel A Tennant; Christian Ludwig; Gareth G Lavery Journal: Wellcome Open Res Date: 2018-11-15